title: Second European Round Table on the Future Management of HIV: 10-11 October 2014, Barcelona, Spain.
abstract: The Second European Round Table on the Future Management of HIV took place in Barcelona, 10-11 October 2014 and focused on the HIV-1 reservoir, strategies for HIV cure and primary HIV infection (PHI). Important issues in the HIV-1 reservoir research field are the validity of reservoir measurement techniques and the potential of new drugs to target latently infected cells. Current HIV-1 cure concepts are based on theoretical assumptions of biologically plausible mechanisms, supported by several clinical observations. Three main potential strategies are under investigation in order to achieve a sterilising cure or maintain HIV-1 remission: latency reversal resulting in antigen expression and viral cytolysis or immune targeted cell-death; immunological control of the reservoir; or replacement of the complete autologous haematopoietic and lymphoid stem-cell repertoire by transplantation. An interesting opportunity for restricting the size of the reservoir entails the early initiation of antiretroviral treatment (ART) during PHI. In terms of the reservoir, early treatment limits its size, alters its composition, and restricts the genetic variability of integrated proviral HIV-1 DNA. The challenges ahead involve the identification of patients undergoing seroconversion to HIV-1 and the prompt initiation of treatment. How the seemingly beneficial impact of early treatment will make cure more feasible, and whether the positive effects of the cure efforts outweigh the potentially negative impact of life-long ART, are important aspects of future collaborative research prospects.
authors.affiliation: Erasmus Medical Center , Erasmus University , Rotterdam , the Netherlands.
authors.forename: Casper
authors.initials: C
authors.lastname: Rokx
authors.affiliation: VA San Diego Healthcare System and University of California , San Diego , USA.
authors.forename: Douglas D
authors.initials: DD
authors.lastname: Richman
authors.affiliation: Institut Pasteur , Paris , France.
authors.forename: Michaela
authors.initials: M
authors.lastname: Müller-Trutwin
authors.affiliation: Emory University School of Medicine , Atlanta , USA.
authors.forename: Guido
authors.initials: G
authors.lastname: Silvestri
authors.affiliation: University Medical Center Hamburg-Eppendorf , Hamburg , Germany.
authors.forename: Jan
authors.initials: J
authors.lastname: Lunzen
authors.affiliation: University of Liverpool , UK.
authors.forename: Saye
authors.initials: S
authors.lastname: Khoo
authors.affiliation: Massachusetts General Hospital and Harvard Medical School , Boston , MA , USA.
authors.forename: Mathias
authors.initials: M
authors.lastname: Lichterfeld
authors.affiliation: Heinrich-Pette-Institut , Hamburg , Germany.
authors.forename: Marcus
authors.initials: M
authors.lastname: Altfeld
authors.affiliation: University of Rome , Italy.
authors.forename: Carlo Federico
authors.initials: CF
authors.lastname: Perno
authors.affiliation: University of California , San Francisco , USA.
authors.forename: Peter W
authors.initials: PW
authors.lastname: Hunt
authors.affiliation: University College Dublin , Ireland.
authors.forename: Paddy
authors.initials: P
authors.lastname: Mallon
authors.affiliation: University of Bonn , Germany.
authors.forename: Jürgen K
authors.initials: JK
authors.lastname: Rockstroh
authors.affiliation: Chelsea and Westminster Hospital , London , UK.
authors.forename: Anton L
authors.initials: AL
authors.lastname: Pozniak
authors.affiliation: Unitat VIH, Irsicaixa Foundation , Hospital Universitari Germans Trias i Pujol, UAB, UVIC-UCC , Badalona , Catalonia , Spain.
authors.forename: Bonaventura
authors.initials: B
authors.lastname: Clotet
authors.affiliation: Viroscience, Erasmus Medical Center , Erasmus University , Rotterdam , the Netherlands.
authors.forename: Charles Ab
authors.initials: CA
authors.lastname: Boucher
keywords: ART; HIV reservoir; HIV-1; HIV-1 cure; HIV-1 latency; animal models; gene therapy; inflammation; pharmacokinetics; primary HIV-1 infection